Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective cohort study, researchers found that patients with androgenetic alopecia using 5α-reductase inhibitors had a significantly higher risk of developing dry eye disease compared to those not using these medications.

This review highlighted the pharmacological potential of Mor, noting its protective effects on the kidneys, liver, bones, nervous system, heart, digestive system, skin, and lungs, as well as its anti-obesity and anti-inflammatory properties, revealing areas for future research.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

Oral retinoids are effective for severe skin conditions but require careful use due to side effects.

In this animal study, petroleum ether and ethanolic extracts of Abrus precatorius seeds appeared to reverse androgen-induced alopecia in male albino rats by inhibiting the 5α-reductase enzyme, similar to finasteride.

In this integrative narrative review, researchers reported that aromatase inhibition using dutasteride and Serenoa repens after hair transplant can effectively preserve follicles and minimize side effects, suggesting personalized strategies may optimize clinical outcomes and patient satisfaction.

This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This study suggests that three mushroom-derived bioactive compounds, Zhankuic acid A, Sterenin M, and Melleolide K, may effectively inhibit SRD5A2 and stabilize its interaction, indicating potential for treating androgenic alopecia.

This study developed and validated a label-free assay using LC-MS to screen for S5αR inhibitors, identifying Thai herbal extracts, Impatiens balsamina L. and Curcuma longa L., as promising sources.

This study found that the small signaling peptide RALF22 plays a key role in root hair growth response to volatile compounds emitted by Penicillium aurantiogriseum through ethylene, auxin, and photosynthesis signaling in Arabidopsis.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

In this study, Japanese patients with alopecia areata were found to have higher BMI and retinol intake, with retinol intake predicting severity of hair loss.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

This study found that a composition including Serenoa repens extract and anti-inflammatory agents effectively suppressed inflammation-related gene expression in a keratinocyte model, suggesting a potential dual strategy for treating androgenetic alopecia.

This review discusses the roles of the Agouti and Agouti-related proteins in pigmentation and energy regulation and reports no new experimental findings.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This study found that inhibiting arachidonate 12-lipoxygenase (ALOX12) may enhance hair cuticle maturation by increasing S100A3 protein citrullination and promoting cuticular differentiation in isolated human hair follicles.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

This review discusses the potential role of thyroid receptor β agonists in treating androgenetic alopecia, reporting no new clinical results while highlighting their mechanism and anti-alopecia efficacy.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This study found that the ethanolic root extract of Onosma dichroantha exhibits antioxidant activity and significant antimicrobial effects against 11 bacterial species.

In this computational study, the researchers observed that compounds in rosemary extract showed promising interactions with proteins involved in androgenic alopecia, suggesting potential for hair growth promotion and hair loss prevention, warranting further in vitro and in vivo validation.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.